Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia

• Hauptverfasser: Xia Pu (Verfasst von), Mark Sale (Verfasst von), Feng Yang (Verfasst von), Yi Zhang (Verfasst von), John D. Davis (Verfasst von), Nidal Al‐Huniti (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2021-11-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). This work characterized the population pharmacokinetics (PK)/pharmacodynamics...